Type 2 diabetes mellitus (T2DM) affects an estimated 29 million Americans and 463 million people worldwide, with that number projected to increase to 700 million by 2045. As approximately 40% of patients with T2DM develop chronic kidney disease (CKD), this has led to CKD being one of the most common diabetes complications, exposing patients to a 3-fold risk of cardiovascular death compared to those with T2DM alone. Also, most patients do not know that they have CKD until it is in an advanced stage. At minimal, yearly screening for eGFR and UACR in all patients with T2DM is recommended by the major kidney and diabetes guidelines to detect decline in the function of and damage to the kidneys; however, many patients do not receive these important screenings, resulting in delayed diagnosis and poorer outcomes for these unrecognized patients. The heavy burden of diabetes-associated CVD has become more widely acknowledged in recent years, leading to a shift in the T2DM management guidelines that includes a focus on early diagnosis and management of CKD in patients with T2DM.
The first episode of this CMEO BriefCase series on halting drivers of CKD progression will present a case study that will show when a patient with T2DM should undergo guideline-recommended screening with urine albumin excretion (UACR) and estimated glomerular filtration rate (eGFR) for early diagnosis of CKD.
At the end of this CME/CE activity, participants should be able to recognize when a patient should undergo guideline-recommended screening with UACR and eGFR for early diagnosis of CKD in patients with T2DM.
Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Patel reports that he is on the speakers bureau for Abbott; Amarin Corporation; AstraZeneca; Bayer; Boehringer Ingelheim; Dexcom, Inc.; Lilly; Novo Nordisk; Xeris Pharmaceuticals, Inc.; and Zealand Pharma.
Dr. Isaacs reports that she is on the speakers bureau for Abbot; Bayer Healthcare; Dexcom, Inc; Insulet Corporation; Medtronic; and Novo Nordisk. She reports that she is a consultant for DiabetesWise; The diaTribe Foundation; Tempramed; and Undermyfork.
Disclosures were obtained from the CME Outfitters, LLC, staff; no disclosures to report:
CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Call us at 877.CME.PROS (877.263.7767).